Royalty Pharma Newsroom

Royalty Pharma Is Maintained at Buy by Citigroup

Dow JonesOct 25 14:38 ET

Royalty Pharma Analyst Ratings

BenzingaOct 25 14:27 ET

Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $51

Moomoo NewsOct 11 08:34 ET

TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42

Moomoo NewsOct 8 02:31 ET

Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $51

Moomoo NewsSep 4 14:31 ET

Royalty Pharma Analyst Ratings

BenzingaAug 14 07:14 ET

Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $51

Moomoo NewsAug 13 10:32 ET

Buy Rating Affirmed for Royalty Pharma Amidst Strong Financials and Positive Growth Outlook

TipRanksAug 13 09:47 ET

Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Royalty Pharma (RPRX)

TipRanksAug 11 23:05 ET

Analysts Are Bullish on These Healthcare Stocks: Royalty Pharma (RPRX), Arcellx Inc (ACLX)

TipRanksAug 9 09:53 ET

Royalty Pharma (RPRX) Receives a Buy From Morgan Stanley

TipRanksAug 9 09:52 ET

Royalty Pharma Analyst Ratings

BenzingaJul 11 13:17 ET

Morgan Stanley Sticks to Its Buy Rating for Royalty Pharma (RPRX)

TipRanksJul 11 08:49 ET

Royalty Pharma Analyst Ratings

BenzingaJun 3 11:51 ET

UBS Downgrades Royalty Pharma to Neutral, Announces $28 Price Target

BenzingaJun 3 11:50 ET

Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Royalty Pharma (RPRX)

TipRanksMay 28 20:23 ET

Royalty Pharma's Strategic Acquisitions and Compelling Valuation Warrant a Buy Rating

TipRanksMay 28 20:03 ET

Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)

TipRanksMay 10 11:20 ET

Royalty Pharma Analyst Ratings

BenzingaApr 12 08:03 ET

JPMorgan Cuts Price Target on Royalty Pharma to $42 From $45, Keeps Overweight Rating

MT NewswiresFeb 20 11:43 ET